TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

• Status: Completed
• Trial end date: 2020-11-09

Summary

The purpose of this study is to assess the efficacy and safety of ruxolitinib cream in adolescents and adults with atopic dermatitis (AD).

• Phase: Phase 3

Details

• Lead Sponsor: Incyte Corporation